v3.26.1
Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Research and development expenses $ 2,337,308 $ 2,165,092
General and administrative expenses 1,969,244 1,980,207
Total operating expenses 4,306,552 4,145,299
Loss from operations (4,306,552) (4,145,299)
Operating Segments [Member]    
Segment Reporting [Line Items]    
Change Increase (Decrease), Research and development expenses 173,000  
Research and development expenses $ 2,338,000 2,165,000
Change Increase (Decrease), Research and development expenses, percentage 8.00%  
General and administrative expenses $ 1,969,000 1,980,000
Change Increase (Decrease), General and administrative expenses $ (11,000)  
Change Increase (Decrease), General and administrative expenses, percentage (0.60%)  
Total operating expenses $ 4,307,000 4,145,000
Change Increase (Decrease), Operating expenses $ 162,000  
Change Increase (Decrease), Operating expenses, percentage 3.90%  
Loss from operations $ (4,307,000) (4,145,000)
Change Increase (Decrease), Loss from operations $ (162,000)  
Change Increase (Decrease), Loss from operations, percentage (3.90%)  
Operating Segments [Member] | Clinical Research [Member]    
Segment Reporting [Line Items]    
Subtotal $ 798,000 846,000
Change Increase (Decrease), Research and development expenses $ (48,000)  
Change Increase (Decrease), Subtotal, percentage (5.70%)  
Operating Segments [Member] | Clinical Research [Member] | OVATION 2 and MRD Trials [Member]    
Segment Reporting [Line Items]    
Subtotal $ 105,000 134,000
Change Increase (Decrease), Research and development expenses $ (29,000)  
Change Increase (Decrease), Subtotal, percentage (21.60%)  
Operating Segments [Member] | Clinical Research [Member] | Ovation Three [Member]    
Segment Reporting [Line Items]    
Subtotal $ 101,000 80,000
Change Increase (Decrease), Research and development expenses $ 21,000  
Change Increase (Decrease), Subtotal, percentage 26.30%  
Operating Segments [Member] | Clinical Research [Member] | Placcine Vaccine [Member]    
Segment Reporting [Line Items]    
Subtotal $ 3,000 58,000
Change Increase (Decrease), Research and development expenses $ (55,000)  
Change Increase (Decrease), Subtotal, percentage (94.60%)  
Operating Segments [Member] | Clinical Research [Member] | Other Clinical and Regulatory [Member]    
Segment Reporting [Line Items]    
Subtotal $ 589,000 574,000
Change Increase (Decrease), Research and development expenses $ 15,000  
Change Increase (Decrease), Subtotal, percentage 2.60%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member]    
Segment Reporting [Line Items]    
Subtotal $ 1,540,000 1,319,000
Change Increase (Decrease), Research and development expenses $ 221,000  
Change Increase (Decrease), Subtotal, percentage 16.80%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Ovation [Member]    
Segment Reporting [Line Items]    
Subtotal $ 1,293,000 913,000
Change Increase (Decrease), Research and development expenses $ 380,000  
Change Increase (Decrease), Subtotal, percentage 41.60%  
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Manufacturing (CMC) [Member]    
Segment Reporting [Line Items]    
Subtotal $ 247,000 $ 406,000
Change Increase (Decrease), Research and development expenses $ (159,000)  
Change Increase (Decrease), Subtotal, percentage (39.20%)